Chemoprevention of 1,2-dimethylhydrazine-induced colon carcinogenesis by a non-steroidal anti-inflammatory drug, etoricoxib, in rats: Inhibition of nuclear factor κB

Asian Pacific Journal of Cancer Prevention

Volumn 10, Issue 6, 2009, Pages 1141-1146

  Tanwar, Lalita ^a   Vaish, Vivek ^a   Sanyal, S N ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

Acf; apoptosis; Colon cancer; COX 2 expression; Etoricoxib; Nf b; Nsaid

Indexed keywords

1,2 DIMETHYLHYDRAZINE; ETORICOXIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; PYRIDINE DERIVATIVE; SULFONE;

ANIMAL; APOPTOSIS; ARTICLE; CHEMICALLY INDUCED DISORDER; CHEMOPROPHYLAXIS; COLON TUMOR; DRUG ANTAGONISM; DRUG EFFECT; FLUORESCENCE MICROSCOPY; IMMUNOHISTOCHEMISTRY; MALE; RAT; SPRAGUE DAWLEY RAT; WESTERN BLOTTING;

1,2-DIMETHYLHYDRAZINE; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; APOPTOSIS; BLOTTING, WESTERN; CHEMOPREVENTION; COLONIC NEOPLASMS; IMMUNOHISTOCHEMISTRY; MALE; MICROSCOPY, FLUORESCENCE; NF-KAPPA B; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; SULFONES;

EID: 77956627421     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Aggarwal BB (2004). Nuclear factor κB: the enemy within. Cancer Cell, 6, 203-8.
2. Baeuerle PA, Baltimore D (1996). NF-kappa B: ten years after. Cell, 87, 13-20.
3. Baldwin AS (2001). Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest, 107, 241-6.
4. Bodelon C, Doherty JA, Chen C, Rossing MA, Weiss NS (2009). Use of nonsteroidal anti-inflammatory drugs and risk of endometrial cancer. Am J Epidemiol, 170, 1512-7.
5. Bonizzi G, Karin M (2004). The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol, 25, 280-8.
6. Bradford MM (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the priniciple of protein-dye binding. Anal Biochem, 72, 248-254.
7. Corpet DE, Tache S (2002). Most effective colon cancer chemopreventive agents in rats: a review of aberrant crypt foci and tumour data, ranked by potency. Nutr Cancer, 43, 1-21.
8. Craven PA, DeRobertis FR (1992). Effects of aspirin on 1,2-dimethylhydrazine-induced colon carcinogenesis. Carcinogenesis, 13, 541-6.
9. Donnelly MT, Hawkey CJ (1997). Review article: COX-II inhibitors, a new generation of safer NSAIDs? Aliment Pharmacol Ther, 11, 227-236.
10. Ghosh S, May MJ, Kopp EB (1998). NF-kappa B and Rel proteins: volutionarily conserved mediators of immune responses. Annu Rev Immunol, 16, 225-260.
11. Higuchi Y, Tanii H, Koriyama Y, Mizukami Y, Yoshimoto T (2007). Arachidonic acid promotes glutamate-induced cell death associated with necrosis by 12- lipoxygenase activation in glioma cells. Life Sci, 80, 1856-64.
12. Kanwar SS, Vaiphei K, Nehru B, Sanyal SN (2008). Antioxidative effects of non-steroidal anti-inflammatory drugs during the initiation stages of experimental colon carcinogenesis in rats. J Environ Pathol Toxicol Oncol, 27, 89-100.
13. Kerr JFR, Winterford CM, Harmon BV (1994). Apoptosis. Its significance in cancer and cancer therapy. Cancer, 73, 2013-26.
14. Khan MN, Lee YS (2009). Cyclooxygenase inhibitors: Scope of their use and development in cancer chemotherapy. Med Res Rev, (in Press).
15. Marnett LJ (1992). Aspirin and the potential role of prostaglandin in colon cancer. Cancer Res, 52, 5575-89.
16. Moorghen M, Ince P, Finney KJ, et al (1988). A protective effect of sulindac against chemically-induced primary colonic tumours in mice. J Pathol, 156, 341-7.
17. Mouille B, Robert V, Blachier F (2004). Adaptive increase of ornithine production and decrease of ammonia metabolism in rat colonocytes and hyperproteic diet ingestion. Am J Physiol, 287, 344-51.
18. Pahl HL (1999). Activators and target genes of Rel/NF-kappa B transcription factors. Oncogene, 18, 6853-66.
19. Park H-S, Goodlad RA, Wright NA (1997). The incidence of aberrant crypt foci and colonic carcinoma in dimethyl hydrazine treated rats varies in a site-specific manner and depends on tumor histology. Cancer Res, 57, 4507-10.
20. Pereira MA, Barnes LH, Rassman VL, Kelloff GV, Steele VE (1994). Use of azoxymethane-induced foci of aberrant crypts in rat colon to identify potential cancer chemopreventive agents. Carcinogenesis, 15, 1049-54.
21. Pretlow TP, O'Riordan MA, Pretlow TG, Stellato TA (1992). Aberrant crypts in human colonic mucosa: Putative preneoplastic lesions. J Cell Biochem, 16G, 55-62.
22. Reddy BS, Rao CV, Rivenson A, Kelloff G (1993). Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats. Carcinogenesis, 14, 1493-7.
23. Riendeau D, Percival MD, Brideau C, et al (2001). Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J Pharmacol Exp Ther, 296, 558-66.
24. Roediger WEW, Truelove SC (1979). Method of preparing isolated colonic epithelia cells (colonocytes) for metabolic studies. Gut, 20, 484-8.
25. Sawhney M, Rohatgi N, Kaur J, et al (2007). Expression of NFkappa B parallels COX-2 expression in oral precancer and cancer: association with smokeless tobacco. Int J Cancer, 120, 2545-56.
26. Sharma P, Kaur J, Sanyal SN (2010). Effect of etoricoxib, a cyclooxygenase-2 selective inhibitor on aberrant crypt formation and apoptosis in 1,2 dimethyl hydrazine induced colon carcinogenesis in rat model. Nutr Hosp, 25, 39-48.
27. Shattuck-Brandt RL, Varilek GW, et al (2000). Cyclooxygenase 2 expression is increased in the stroma of colon carcinomas from IL-10(-/-) mice. Gastroenterology, 118, 337-45
28. Sheng H, Shao J, Morrow JD Beauchamp RD, DuBois RN (1998). Modulation of apoptosis and BCl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res, 58, 362-6.
29. Smalley WE, DuBois RN (1997). Colorectal cancer and nonsteroidal anti-inflammatory drugs. FEBS J, 11, 234-47.
30. Stark LA, Reid K, Sansom OJ (2007). Aspirin activates the NFkappaB signalling pathway and induces apoptosis in intestinal neoplasia in two in vivo models of human colorectal cancer. Carcinogenesis, 28, 968-78.
31. St-Germain ME, Gagnon V, Parent S, Asselin E (2004). Regulation of COX-2 protein expression by Akt in endometrial cancer cells is mediated through NF-kappaB/Ikappa B pathway. Mol Cancer, 11, 3-7.
32. Takayama T, Katsuki S, Takahashi Y (1998). Aberrant crypt foci of the colon as precursors of adenoma and cancer. N Engl J Med, 339, 1277-84.
33. Tanabe T, Tohnai N (2002). Cyclooxygenase isozymes and their gene structures and expression. Prostaglandins Other Lipid Mediat, 68-69, 95-114.
34. Vandoros GP, Konstantinopoulos PA, Sotiropoulou-Bonikou G, et al (2006). PPAR-gamma is expressed and NF-κB pathway is activated and correlates positively with COX-2 expression in stromal myofibroblasts surrounding colon adenocarcinomas. J Cancer Res Clin Oncol, 132, 76-84.
35. Wong S, Lee SJ, Frierson MR, Proch J, et al (1992). Antiarthritic profile of BF-389-A novel anti-inflammatory agent with low ulcerogenic liability. Agents Actions, 37, 90-8.
36. Wyllie AH, Kerr JFR, Currie A (1972). Cell death: the significance of apoptosis. Int Rev Cytol, 68, 251-306.
37. Yuan Y, Zhi-Quiang GE, Jing-Chuan L (2002). Differentiation of apoptotic and necrotic cells in suspension cultures of Taxus cuspidate by the combined use of fluorescent dying and histochemical staining methods. Biotechnol Lett, 24, 71-76.